Thyroid function test variability and cardiovascular morbidity in hyperthyroidism
Clinical Endocrinology · 2023
DOI: 10.1111/cen.14948 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2023. Verfasst von Nelli Suonsyrjä und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Graves Disease, Hyperthyroidism, Cardiovascular Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The variability of thyroid function tests (TFTs) during antithyroid drug (ATD) therapy and its association with adverse health outcomes have not been previously studied. The aim of this study was to evaluate the association of TFT variability and cardiovascular morbidity during ATD therapy.
Design
Retrospective cohort study. Patients and Measurements Hyperthyroid patients ( n = 394) treated with ATD therapy at Tampere University Hospital between March 2016 and December 2018 were followed up for a median time of 1.5 years (interquartile range 0.8–2.0). The coefficients of variation (CVs) of the follow‐up thyroid‐stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) measurements were determined. The associations of TFT variability and baseline clinical factors with cardiovascular disease (CVD) ‐associated hospital visits were assessed with logistic regression analyses.
Results
In the multivariable analyses, age (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 1.03–1.09), male gender (OR: 2.33, 95% CI: 1.03–5.28) and fT4‐CV (OR: 1.02, 95% CI: 1.01–1.04) were independent risk factors for cardiovascular morbidity, whereas baseline positive thyrotropin receptor antibodies (TRAbs) were associated with lower cardiovascular morbidity (OR: 0.29, 95% CI: 0.14–0.61). When the patients with baseline TRAb positivity were studied separately, fT4‐CV was associated with cardiovascular morbidity (OR: 1.03, 95% CI: 1.00–1.05).
Conclusions
During ATD therapy, fT4 variability is associated with an increased cardiovascular morbidity. Although positive TRAbs are associated with a lower cardiovascular morbidity compared with hyperthyroidism with negative autoantibodies, the variability of fT4 is associated with cardiovascular morbidity also in patients with positive TRAbs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Department of Internal Medicine, Faculty of Social Sciences, Tampere University, Tampere, Finland.
- Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
- Division of Internal Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland.
Zitieren
APA
Suonsyrjä, N., Laihia, I., Huhtala, H., Jaatinen, P., & Metso, S. (2023). Thyroid function test variability and cardiovascular morbidity in hyperthyroidism. Clinical Endocrinology. https://doi.org/10.1111/cen.14948
Vancouver
Suonsyrjä N, Laihia I, Huhtala H, Jaatinen P, Metso S. Thyroid function test variability and cardiovascular morbidity in hyperthyroidism. Clinical Endocrinology. 2023. doi:10.1111/cen.14948
BibTeX
@article{Suonsyrj2023,
author = {Suonsyrjä, Nelli and Laihia, Iina and Huhtala, Heini and Jaatinen, Pia and Metso, Saara},
title = {Thyroid function test variability and cardiovascular morbidity in hyperthyroidism},
journal = {Clinical Endocrinology},
year = {2023},
doi = {10.1111/cen.14948}
}
EUVIMED